Effects of rabeprazole, lansoprazole and omeprazole on intragastric ph in CYP2C19 extensive metabolizers
|
|
- Jessica Parsons
- 5 years ago
- Views:
Transcription
1 Aliment Pharmacol Ther 2002; 16: doi: /j x Effects of rabeprazole, lansoprazole and omeprazole on intragastric ph in CYP2C19 extensive metabolizers T. SAITOH*, Y. FUKUSHIMAà, H. OTSUKA*, J. HIRAKAWA*, H. MORI*, T. ASANOà, T. ISHIKAWAà, T. KATSUBE, K. OGAWA & S. OHKAWA* Departments of *Internal Medicine and Surgery, Tokyo Women s Medical University, Daini Hospital, Tokyo, Japan; àdepartment of Internal Medicine, Faculty of Medicine, University of Tokyo, Tokyo, Japan Accepted for publication 5 July 2002 SUMMARY Aim: To investigate the inhibitory effects on gastric acid secretion of three proton pump inhibitors, omeprazole, lansoprazole and rabeprazole, using a three-way crossover design in healthy Helicobacter pylori-negative, 1 S-mephenytoin 4 -hydroxylase (CYP2C19) homo- and hetero-extensive metabolizers. Methods: Eight healthy Japanese male volunteers were enrolled. After the administration of rabeprazole (10 mg day), lansoprazole (30 mg day) or omeprazole (20 mg day), intragastric ph monitoring was commenced from 24 h before the first proton pump inhibitor dose, and continued for days 1 3 after proton pump inhibitor administration. The ph electrode was used for 48 h and changed just before ph monitoring on day 2. Results: For the administration of 10 mg day rabeprazole, the mean ratios of the 24-h ph 3 holding time were 5.7 ± 1.1%,13.6 ± 2.2%, 35.3 ± 2.7% and 62.8 ± 3.1% for the pre-treatment day and days 1, 2 and 3, respectively. The same ratios for lansoprazole (30 mg day) were 5.7 ± 0.7%, 7.4 ± 1.5%, 13.6 ± 3.4% and 26.6 ± 4.9%; the same ratios for 20 mg day omeprazole were 5.9 ± 0.9%, 6.1 ± 1.2%, 11.4 ± 2.8% and 16.4 ± 4.6%. The mean ratio of the 24-h ph 3 holding time of days 1 3 increased significantly compared to the pre-treatment day (P < 0.01) with the administration of rabeprazole and lansoprazole. The magnitude of inhibition of gastric acid secretion after rabeprazole administration was stronger than that after lansoprazole. A significant elevation of the mean ratio of the 24-h ph 3 holding time was demonstrated on days 2 and 3 with omeprazole (P < 0.01). Conclusions: In H. pylori-negative CYP2C19 extensive metabolizers, rabeprazole (10 mg day) shows a faster onset of rising intragastric ph and a stronger inhibition of gastric acid secretion than do lansoprazole (30 mg day) or omeprazole (20 mg day). INTRODUCTION Proton pump inhibitors, such as omeprazole, lansoprazole and rabeprazole, have been widely used for the treatment of acid-related disease. Comparative studies Correspondence to: Dr T. Saitoh, Department of Internal Medicine, Tokyo Women s Medical University, Daini Hospital, Nishiogu, Arakawa-ku, Tokyo , Japan. ssumiko@fa2.so-net.ne.jp have demonstrated that proton pump inhibitors provide acid secretion, pain relief and ulcer healing superior to those achieved with histamine H 2 -receptor antagonists. 1 Although many studies have shown that multiple administration (usually more than 7 days) of proton pump inhibitors provides a sufficient intragastric ph for the relief of pain, ulcer healing and the eradication of Helicobacter pylori, 2 5 few reports have discussed the changes in gastric ph monitored in the early post-administration phase or the patterns of Ó 2002 Blackwell Science Ltd 1811
2 1812 T. SAITOH et al. changes in the gastric ph analysed before the occurrence of the maximal inhibition of gastric acid secretion. Although changes in gastric ph in the early postadministration phase have been examined, the timing of the elevation of gastric ph and the patterns of changes in the ph have varied widely between studies. In the daily clinical setting, a faster onset of rising intragastric ph and a stronger inhibition of gastric acid secretion of proton pump inhibitors may be crucial for symptomatic relief in patients with peptic ulcers and gastro-oesophageal reflux disease. There are some differences between proton pump inhibitors with regard to their potency and the time from the onset of the inhibition of acid secretion until they show a clinical effect. This is due to differences in the rate of acid-induced chemical activation of proton 2 pump inhibitors to their respective cyclic sulphenamide or metabolic pathways as a result of differences in 3 molecular structure. 6, 7 Recently, subject-related factors, such as H. pylori infection and S-mephenytoin 44 -hydroxylase (CYP2C19) genotype, have been reported to influence the inhibitory action of proton pump inhibitors on gastric acid secretion in the early postadministration phase It has been reported that the inhibitory action of omeprazole on gastric acid secretion decreases after successful eradication therapy in H. pylori-positive subjects This indicates that H. pylori infection of the gastric mucosa potentiates the effects of proton pump inhibitors. Proton pump inhibitors are inactivated by metabolism in the liver, especially by CYP2C19 and CYP3A4 of cytochrome P450 (CYP), and differences in the metabolic profiles between proton pump inhibitors and in the metabolic capacities of subjects could have a profound influence on drug efficacy. Indeed, large differences in plasma drug levels have been shown between CYP2C19 extensive metabolizers and poor metabolizers, and these also influence the degree of inhibition of acid secretion. Furuta et al. reported that, when the gastric ph was measured following the oral administration of omeprazole to H. pylori-negative subjects, significantly lower mean gastric ph levels were observed in extensive metabolizers than in poor metabolizers. 14 Although rabeprazole is also a substituted benzimidazole sulphoxide, the drug has a different metabolic profile compared to that of the other proton pump inhibitors. Rabeprazole is metabolized mainly via a non-enzymatic reduction to the thioether rabeprazole, and CYP2C19 and CYP3A4 are only partly involved in the metabolism of rabeprazole. 9 Therefore, the acid inhibitory effect of rabeprazole is supposed to be less influenced by the CYP2C19 phenotype or genotype status compared to that of other proton pump inhibitors, such as lansoprazole or omeprazole. Recently, Shirai et al. have studied the influence of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric ph, and have concluded that the acid inhibitory effects of omeprazole and rabeprazole are significantly dependent on the CYP2C19 genotype status, as well as on their intrinsic pharmacokinetic and pharmacodynamic characteristics and dosing schemes. 7 Rabeprazole shows a greater and faster acid inhibitory effect than omeprazole; 2, 7 however, there are few data available on the comparison of the acid inhibitory effects of rabeprazole and lansoprazole. 6 We believe that CYP2C19 extensive metabolizers would be more suitable for the differentiation and evaluation of the acid inhibitory effects of proton pump inhibitors. Therefore, we investigated the effects of rabeprazole, lansoprazole and omeprazole on intragastric ph in CYP2C19 extensive metabolizers in the early phase of the post-administration period by continuous monitoring of the gastric ph from 24 h prior to the administration of the proton pump inhibitor to the third day after administration. SUBJECTS AND METHODS Subjects The subjects were eight healthy male volunteers, aged between 24 and 48 years and weighing kg. All volunteers gave written informed consent, and the study was conducted in accordance with the Declaration of Helsinki. The subjects were all negative for anti- H. pylori immunoglobulin G antibodies (SRL Inc, Tokyo, Japan), confirmed by the 13 C-urea breath test (Ubit- IR200, Ohtsuka Electronics, Tokyo, Japan). CYP2C19 genotyping DNA samples were obtained from the eight individuals. The samples were analysed by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method to detect the CYP2C19 genotype according to a previously reported technique. 15 It has been reported that there are two point mutations in the CYP2C19 gene. The wild-type allele has G at position
3 INTRAGASTRIC ph AFTER PPI ADMINISTRATION in exon 4 and G at position 689 in exon 5 of CYP2C19. One (m1 allele) of the mutated alleles has A at position 689 in exon 5. Another mutated allele (m2 16, 17 allele) has A at position 636 in exon 4. Four individuals were genotyped as homozygous extensive metabolizers (homo-extensive metabolizers) who had two wild-type alleles. Another four individuals were genotyped as heterozygous extensive metabolizers (hetero-extensive metabolizers) who had one wild-type allele and one m1 allele (SRL Inc, Tokyo, Japan). Study protocol The first 24 h of intragastric ph monitoring in all subjects represented the pre-treatment period. Rabeprazole (10 mg) (Pariet, Eisai Co. Ltd, Tokyo, Japan), lansoprazole (30 mg) (Takepron, Takeda Co. Ltd, Osaka, Japan) or omeprazole (20 mg) (Omepral, Fujisawa Pharmaceutical Co. Ltd, Osaka, Japan) was administered the following day 30 min after the evening meal, and the same agent was administered on days 2 and 3 at around the same time. The order of administration of the test agents for each subject was randomized in a crossover manner. The washout periods between studies were at least 2 weeks, and so each subject completed the study on all three test drugs within a 4-month period. Subjects were instructed to take three meals a day: dinner at h, breakfast at h and lunch at h. Meals were not standardized, but subjects were asked to keep the contents of each meal as similar as possible. 48-h ph-metry The ph electrode was inserted transnasally under local anaesthesia and positioned fluoroscopically, so that the electrode was located in the body of the stomach, 5 cm distal to the cardia. Monitoring was performed continuously for 48 h from h, after which time the ph electrode was changed over within 40 min, and monitoring was continued for a further 48 h. The gastric ph was measured at 10-s intervals by a portable ph meter attached to the glass ph electrode (Chemical Instrument Co. Ltd, Tokyo, Japan). The ph electrode was calibrated before each recording using standard buffer solutions of ph 1.68 and ph At the end of each recording, the data were transferred to a personal computer and stored until analysed with the software (Chemical Instrument Co. Ltd, Tokyo, Japan). The 24-h monitoring period was divided into daytime ( h) and night-time ( h) periods. Table 1. Intragastric ph 3 holding time (%) after the administration of proton pump inhibitors for 3 days Treatment (dose day) Study period (time) ph 3 holding time (%) Baseline Day 1 Day 2 Day 3 Rabeprazole 24 h 5.74 ± } 2.22* } 2.67* ± 3.12* (10 mg day) ( h) ( ) ( ) ( ) ( ) Night-time; 8 h ± 3.27* ± 5.97* ( h) ( ) ( ) Daytime; 16 h ± ± 4.45* ± 3.99* ± 3.50* ( h) ( ) ( ) ( ) ( ) Lansoprazole 24 h 5.66 ± ± 1.49* ± 3.42* ± 4.87* (30 mg day) ( h) ( ) ( ) ( ) ( ) Night-time; 8 h ± 4.93* ( h) ( ) Daytime; 16 h ± ± 3.35* ± 7.77* ± 8.69* ( h) ( ) ( ) ( ) ( ) Omeprazole 24 h 5.86 ± ± ± 2.79* ± 4.55* (20 mg day) ( h) ( ) ( ) ( ) ( ) Night-time; 8 h ( h) Daytime; 16 h ± ± ± 5.18* ± 8.67* ( h) ( ) ( ) ( ) ( ) Mean ± s.d. (range). * P < 0.01 vs. baseline data.
4 1814 T. SAITOH et al. Statistical analysis A 24-h profile of intragastric ph was obtained for each subject at baseline and on days 1 3 of dosing. The mean percentage of time for which the intragastric ph > 3 (ph 3 holding time) was calculated for each subject during each dosing session and suitable intervals (daytime, h; night-time, h). All numerical data listed in Table 1 are given as the mean ± s.d and (range). Differences in the ph 3 holding time for each day after drug administration were compared with the baseline data using the paired t-test with the Bonferroni method to correct for multiplicity. A P value of less than ( ¼ ) was considered to be statistically significant. Statistical calculations were performed using a SAS software system. RESULTS The mean 24-h intragastric ph profiles for the pretreatment period and days 1, 2 and 3 of the postadministration phase for rabeprazole (10 mg) (top), lansoprazole (30 mg) (middle) and omeprazole (20 mg) (bottom) are shown in Figure 1. The mean percentage of time for which the intragastric ph > 3 (ph 3 holding time, %) after the administration of the three proton pump inhibitors for 3 days is summarized in Table 1. The mean ratios of the 24-h, daytime period and night-time period ph 3 holding time for the pretreatment period and days 1 3 after administration, for each proton pump inhibitor, are shown in Figure 1. The baseline data for the 24-h intragastric ph time curves (Figure 1) and ph 3 holding time (%, Table 1) were fairly similar for the three proton pump inhibitors. After the administration of 10 mg rabeprazole, the mean 24-h intragastric ph time curves showed an elevation by a value of unity overall, and a prolongation of the post-prandial ph elevation in comparison with the baseline data on day 2. On day 3, there was a further prolonged period of ph 3 from the middle of the night to the early morning hours. The mean ratio of the 24-h ph 3 holding time was 5.7 ± 1.1% for the pre-treatment period, which increased to 13.6 ± 2.2%, 35.3 ± 2.7% and 62.8 ± 3.1% for days 1, 2 and 3, respectively. The mean ratio of the ph 3 holding time for days 1 3 increased significantly compared with the baseline data for the 24-h and daytime periods (P < 0.01, Figure 2 and Table 1). Figure 1. Mean 24-h intragastric ph profiles after the administration of 10 mg rabeprazole (top; RPZ), 30 mg lansoprazole (middle; LPZ) and 20 mg omeprazole (bottom; OPZ) for the pretreatment period and on days 1, 2 and 3 after administration in the eight CYP2C19 extensive metabolizers. The thin line represents baseline recordings, the thick line indicates day 1, the dotted line indicates day 2 and the broken line indicates day 3. In the case of 30 mg lansoprazole, the mean 24-h intragastric ph profiles showed a definite increase on days 2 and 3 compared with the pre-treatment period. The mean ratios of the 24-h ph 3 holding time were 5.7 ± 0.7%, 7.4 ± 1.5%, 13.6 ± 3.4% and 26.6 ± 4.9% for the pre-treatment period and days 1, 2 and 3, respectively. A significant increase in the mean ratio of the ph 3 holding time was observed on days 1 3 (P < 0.01, Figure 2 and Table 1). However, the
5 INTRAGASTRIC ph AFTER PPI ADMINISTRATION 1815 Figure 2. The mean ratio of the 24-h, daytime period ( h) and night-time period ( h) ph 3 holding time (%) for the pre-treatment period and days 1, 2 and 3 after administration with each proton pump inhibitor. The filled circle, filled triangle and filled square represent the mean ratio of the ph 3 holding time with 10 mg rabeprazole, 30 mg lansoprazole and 20 mg omeprazole, respectively. Mean ± s.d. *P < 0.01 vs. baseline data. magnitude of the inhibition of gastric acid secretion after rabeprazole administration was stronger than that after lansoprazole administration. With the administration of 20 mg omeprazole, the mean 24-h intragastric ph time curves were similar on days 1 3. A slight increase in the inhibition of gastric acid secretion was found only on day 3. The mean ratios of the 24-h ph 3 holding time were 5.9 ± 0.9%, 6.1 ± 1.2%, 11.4 ± 2.8% and 16.4 ± 4.6% for the pretreatment period and days 1, 2 and 3, respectively. A significant elevation of the mean ratio of the ph 3 holding time was demonstrated on days 2 and 3 with omeprazole (P < 0.01, Figure 2 and Table 1). DISCUSSION In this study, we examined the changes in intragastric ph after the administration of rabeprazole, lansoprazole and omeprazole in the early post-administration phase (days 1 3 of treatment) in H. pylori-negative CYP2C19 extensive metabolizers. We observed that, during the early post-administration phase, rabeprazole showed a faster onset and stronger inhibition of intragastric acid secretion than omeprazole and lansoprazole. A significant increase in intragastric ph 3 over 24 h and during the daytime period ( h) was observed from day 1 with rabeprazole, but not with omeprazole. Lansoprazole also showed a significant increase in intragastric ph 3 over 24 h and during the daytime period; however, the magnitude was smaller than that with rabeprazole. This study supports the reports by Williams et al. 2 and Shirai et al. 7 that the initial dose of rabeprazole (20 mg) has a significantly faster onset of inhibition of intragastric acid secretion than that of omeprazole (20 mg). The present results are also supported by the faster and stronger activation of rabeprazole observed in an in vitro study. This was a study of the half-maximum inhibitory concentration (IC 50 ) of rabeprazole and omeprazole for H +,K + -ATPase in hog gastric vesicles measured using the pyruvate kinase lactate dehydrogenase linked system. Based on this study, the IC 50 values of rabeprazole and omeprazole were 0.07 lm and 0.47 lm, respectively. This result indicates that the inhibitory activity of rabeprazole was 6.5 times higher than that of omeprazole. 18 In addition, in an in vitro study of H +, K + - ATPase inhibitory activity using hog gastric vesicles, rabeprazole showed the complete inhibition of H +,
6 1816 T. SAITOH et al. K + -ATPase within 5 min, 19 whereas lansoprazole and omeprazole inhibited the enzyme activity after 5 min. 18, 19 These results suggest that the acid-induced 6activation rate and intensity of sulphenamide depend on their chemical structure, and that rabeprazole is the fastest and strongest proton pump inhibitor to be activated in the acid environment at ph Lansoprazole (30 mg) and omeprazole (20 mg) showed a 30 60% inhibitory effect on pentagastrinstimulated acid secretion on days 1 and 2 after drug administration, 20 suggesting that rabeprazole may have the potential to inhibit H +, K + -ATPase in a similar manner to lansoprazole and omeprazole. Based on the investigations to date on omeprazole in the early postadministration phase, it is generally understood that the first administered dose inhibits only H +, K + -ATPase present in the canalicular membrane, the actual inhibitory effects on gastric acid secretion develop only after the third dose, and 66% of the maximum acid secretion is inhibited on day 5 after drug administration, depending on the degree of activation of H +,K + - ATPase in the resting phase in wall cells and on the recovery of disulphide bonds between the inhibitors and H +, K + -ATPase. 21 It has also been reported that an inhibitory effect of 20 40% on pentagastrin-stimulated acid secretion developed on day 2 for 20 mg omeprazole administration, and 52% on day 1 and 63% on day 2 for 30 mg lansoprazole, compared with placebo, and that the inhibitory action on H +,K + -ATPase that was activated by pentagastrin stimulation appeared as early as day 1 for 30 mg lansoprazole and on day 2 for 20 mg omeprazole. 20 We found a small increase in the gastric ph at midnight for several hours after the first dose of rabeprazole and the prolongation of higher ph values on days 2 and 3, suggesting a different potency of inhibition of acid secretion for rabeprazole compared with that for lansoprazole and omeprazole. It could be speculated that rabeprazole, with its higher pk a value, inhibits acid secretion more rapidly and more strongly than omeprazole and lansoprazole by inhibiting not only the active H +, K + -ATPase present in canalicular membranes, but also the resting H +,K + -ATPase in the cells. Finally, it is proposed that the faster rates of rabeprazole with regard to both the formation of active intermediates and the inhibition of the total H +, K + - ATPase in parietal cells, compared with lansoprazole and omeprazole, could be responsible for the rapid rise in the gastric ph levels in the early post-administration phase. As the administration of 10 mg rabeprazole shows a faster onset and stronger inhibition of intragastric ph in H. pylori-negative CYP2C19 extensive metabolizers than that obtained with 30 mg lansoprazole or 20 mg omeprazole, rabeprazole may be useful for the faster resolution of symptoms in the treatment of acid-related diseases. ACKNOWLEDGEMENTS This research was supported in part by a grant (to T. Saitoh, no ) from the Ministry of Education, Science and Culture, Japan. REFERENCES 1 Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy 1997; 17: Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998; 12: Bruley Des Varannes S, Levy P, Lartigue S, et al. Comparison of lansoprazole with omeprazole on 24-hour intragastric ph, acid secretion and serum gastrin in healthy volunteers. Aliment Pharmacol Ther 1994; 8: Hartmann M, Theiss U, Huber R, et al. Twenty-four-hour intragastric ph profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment Pharmacol Ther 1996; 10: Geus WP, Mulder PG, Nicolai JJ, et al. Acid-inhibitory effects of omeprazole and lansoprazole in Helicobacter pylori-negative healthy subjects. Aliment Pharmacol Ther 1998; 12: Adachi K, Katsube A, Kawamura T, et al. CYP2C19 genotype status and intragastric ph during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther 2000; 14: Shirai N, Furuta T, Moriyama Y, et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric ph. Aliment Pharmacol Ther 2001; 15: Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet 2000; 38: Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13(Suppl. 3): Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996; 31: Verdu EF, Armstrong D, Idstrom J-P, et al. Effect of curing Helicobacter pylori status on intragastric ph during treatment with omeprazole. Gut 1995; 37:
7 INTRAGASTRIC ph AFTER PPI ADMINISTRATION Labenz J, Tilleburg B, Peitz U, et al. Helicobacter pylori augments the ph-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996; 110: Martinek J, Blum A, Stote M, et al. Effects of pumazole (BY841), a novel reversible proton pump antagonist, and of omeprazole, on intragastric acidity before and after cure of Helicobacter pylori infection. Aliment Pharmacol Ther 1999; 13: Furuta T, Ohashi K, Kosuge K, et al. CYP2C19 genotype status and effect of omeprazole on intragastric ph in humans. Clin Pharmacol Ther 1999; 65: Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4 -hydroxylation in an extended Japanese population. Clin Pharmacol Ther 1996; 60: de Morais SMF, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269: de Morais SMF, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46: Morii M, Takata H, Fujisaki H, et al. The potency of substituted benzimidazoles such as E-3810, omeprazole, Ro to inhibit gastric H +,K + -ATPase is correlated with the rate of acid-activation of the inhibitor. Biochem Pharmacol 1990; 39: Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H +,K + -ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997; 272: Muller P, Goksu A, Fuchs F, et al. Initial potency of lansoprazole and omeprazole tablets on pentagastrin-stimulated gastric acid secretion: a placebo-controlled study in healthy volunteers. Aliment Pharmacol Ther 2000; 14: Modlin IM, Sachs G. Inhibition of the gastric acid pump. In: Modlin IM, Sachs G, eds. Acid Related Diseases. Milan: 8 Schnetztor-Verlag Gmbh D-Konstanz, 1998:
Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric ph
Aliment Pharmacol Ther 2001; 15: 1929±1937. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric ph N. SHIRAI*, T. FURUTA*, Y. MORIYAMA, H.OKOCHI, K.KOBAYASHIà,
More informationReview article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors
Aliment Pharmacol Ther 2003; 17 (Suppl. 1): 10 15. Review article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors J. G. HATLEBAKK Department of Medicine, Haukeland Sykehus,
More informationReview article: pharmacology of esomeprazole and comparisons with omeprazole
Aliment Pharmacol Ther 2003; 17 (Suppl. 1): 5 9. Review article: pharmacology of esomeprazole and comparisons with omeprazole J. DENT Department of Gastroenterology, Hepatology and General Medicine, Royal
More informationIntragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily a randomized, two-way crossover study
Aliment Pharmacol Ther 2005; 21: 963 967. doi: 10.1111/j.1365-2036.2005.02432.x Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily a randomized,
More informationOmeprazole 10mg. Name, Restriction, Manner of administration and form OMEPRAZOLE omeprazole 10 mg enteric tablet, 30 (8332M) Max. Qty.
Omeprazole 10mg Name, Restriction, Manner of administration and form omeprazole 10 mg enteric tablet, 30 (8332M) Gastro-oesophageal reflux disease Name, Restriction, Manner of administration and form omeprazole
More informationOriginal Policy Date
MP 2.04.38 Genetic Testing for Helicobacter pylori Treatment Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return
More informationRpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives
Esomeprazole 20mg Name, Restriction, Manner of esomeprazole 20 mg enteric tablet, 30 (8886Q) (029W) Gastric ulcer Peptic ulcer Treatment Phase: Initial treatment The therapy must be for initial treatment
More informationY. Sakurai*, Y. Mori*, H. Okamoto*, A. Nishimura*, E. Komura*, T. Araki* & M. Shiramoto
Alimentary Pharmacology and Therapeutics Acid-inhibitory effects of vonoprazan 2 mg compared with esomeprazole 2 mg or rabeprazole 1 mg in healthy adult male subjects - a randomised open-label cross-over
More informationRabeprazole is superior to omeprazole for the inhibition of peptone meal-stimulated gastric acid secretion in Helicobacter pylori-negative subjects
Aliment Pharmacol Ther 2003; 17: 1109 1114. doi: 10.1046/j.0269-2813.2003.01573.x Rabeprazole is superior to omeprazole for the inhibition of peptone meal-stimulated gastric acid secretion in Helicobacter
More informationThis PDF is available for free download from a site hosted by Medknow Publications
Research Paper www.ijpsonline.com Inter-Individual Variation in Pharmacokinetics of Proton Pump Inhibitors in Healthy Indian Males SHUBHA RANI AND HARISH PADH* B. V. Patel Pharmaceutical Education and
More informationOptimal Dose of Omeprazole for CYP2C19 Extensive Metabolizers in Anti-Helicobacter pylori Therapy: Pharmacokinetic Considerations
July 2002 Notes Biol. Pharm. Bull. 25(7) 923 927 (2002) 923 Optimal Dose of Omeprazole for CYP2C19 Extensive Metabolizers in Anti-Helicobacter pylori Therapy: Pharmacokinetic Considerations Tomoko KITA,
More informationIntra-gastric ph following single oral administrations of rabeprazole and esomeprazole: double-blind cross-over comparison
Original Article JCBN Journal 0912-0009 1880-5086 the Kyoto, jcbn14-41 10.3164/jcbn.14-41 Original Society Japan of Article Clinical for Free Biochemistry Radical Research and Nutrition Japan Intra-gastric
More informationRpts. GENERAL General Schedule (Code GE)
Pantoprazole 20mg Name, Restriction, Manner of administration and form Pantoprazole 20mg enteric tablet, 30 (8399C) Gastro-oesophageal reflux disease Name, Restriction, Manner of administration and form
More informationHigh use of maintenance therapy after triple therapy regimes in Ireland
High use of maintenance therapy after triple therapy regimes in Ireland K Bennett, H O Connor, M Barry, C O Morain, J Feely Department of Pharmacology & Therapeutics Department of Gastroenterology Trinity
More informationCYP2C19-Proton Pump Inhibitors
CYP2C19-Proton Pump Inhibitors Cameron Thomas, Pharm.D. PGY2 Clinical Pharmacogenetics Resident St. Jude Children s Research Hospital February 1, 2018 Objectives: CYP2C19-PPI Implementation Review the
More information헬리코박터제균요법에있어서 CYP2C19 유전형이판토프라졸과라베프라졸포함치료법에미치는영향. Introduction 울산대학교의과대학서울아산병원소화기내과
The Korean Journal of Helicobacter and Upper Gastrointestinal Research Vol. 8, No. 1, 15-19, July 2008 Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: Comparison between Pantoprazole
More informationSUMMARY INTRODUCTION. Accepted for publication 11 February 2003
Aliment Pharmacol Ther 2003; 17: 1015 1019. doi: 10.1046/j.0269-2813.2003.01550.x A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole,
More informationPharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole
Aliment Pharmacol Ther 2001; 15: 1563±1569. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole T. ANDERSSON*, K. ROÈ HSS, E.BREDBERG & M. HASSAN-ALIN *Clinical Pharmacology,
More informationOral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric ph in healthy subjects
Aliment Pharmacol Ther 2003; 18: 705 711. doi: 10.1046/j.1365-2036.2003.01743.x Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric in healthy subjects D. ARMSTRONG*,
More informationReview article: immediate-release proton-pump inhibitor therapy potential advantages
Aliment Pharmacol Ther 25; 22 (Suppl. 3): 25 3. Review article: immediate-release proton-pump inhibitor therapy potential advantages C. W. HOWDEN Division of Gastroenterology, Northwestern University Feinberg
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): November 22, 2011 Most Recent Review Date (Revised): July 22, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS
More informationSUMMARY INTRODUCTION. Accepted for publication 14 January 2004
Aliment Pharmacol Ther 2004; 19: 655 662. doi: 10.1111/j.1365-2036.2004.01893.x, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric ph and comparison with esomeprazole
More information3. DRUG PROFILES C H 3 H 3 C CH 3. Fig Structure of clarithromycin Chemical name, molecular weight and CAS number
DRUG PRFILES 3. DRUG PRFILES 3.1. CLARITHRMYCIN H 3 C H C H 3 C 2 H 5 C H 3 H H H 3 C N CH3 H Fig. 3.1. Structure of clarithromycin 3.1.1. Synonym 6--Methylerythromycin 3.1.2. Chemical name, molecular
More informationSUMMARY INTRODUCTION. Accepted for publication 4 June 2004
Aliment Pharmacol Ther 24; 2: 899 97. doi: 1.1111/j.1365-236.24.2176.x Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way
More informationGenetic polymorphism of CYP2C19 & therapeutic response to proton pump inhibitors
Review Article Indian J Med Res 127, June 2008, pp 521-530 Genetic polymorphism of CYP2C19 & therapeutic response to proton pump inhibitors A.S. Chaudhry, R. Kochhar* & K.K. Kohli Departments of Biochemistry
More informationPthaigastro.org. Evolution of antisecretory agents. History. Antacids and anticholinergic drugs
Evolution of antisecretory agents uthapong Ukarapol, MD. Division of Gastroenterology Chiang Mai University istory 1823- Prout discovered gastric hydrochloric acid 1875- eidenhain and 1893- Golgi identified
More informationCommittee Approval Date: October 14, 2014 Next Review Date: October 2015
Medication Policy Manual Topic: esomeprazole-containing medications: - Nexium - Vimovo - esomeprazole strontium Policy No: dru039 Date of Origin: May 2001 Committee Approval Date: October 14, 2014 Next
More informationGASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali
GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers
More informationEradication of H. pylori Infection in Patients Allergic to Penicillin Using Triple Therapy with a PPI, Metronidazole and Sitafloxacin
CASE REPORT Eradication of H. pylori Infection in Patients Allergic to Penicillin Using Triple Therapy with a PPI, Metronidazole and Sitafloxacin Takahisa Furuta 1, Mitsushige Sugimoto 2, Mihoko Yamade
More information11/19/2012. Comparison between PPIs G CELL. Risk ratio (95% CI) Patient subgroup. gastrin. S-form of omeprazole. Acid sensitive. coated.
REGULATION OF GASTRIC ACID SECRETION Comparison between PPIs Omeprazole Lansoprazole Rabeprazole Pantoprazole Esomeprazole gastrin G CELL + Acid sensitive Yes T1/2 30-60 minutes Main elimination Enteric
More informationNexium 24HR. Tools and information for you and your pharmacy team NOW OTC FOR FREQUENT HEARTBURN. Consumer Healthcare Pfizer Inc.
NOW OTC FOR FREQUENT HEARTBURN w e N Nexium 24HR P H A R M A S S I S T K I T Tools and information for you and your pharmacy team 2014 Pfizer Inc. NXM041468 05/14 Q: What is the indication for Nexium 24HR
More informationOptimal Management of GERD with Dexlansoprazole - Extended plasma concentration and dosing flexibility with a dual delayed release PPI
Optimal Management of GERD with Dexlansoprazole - Extended plasma concentration and dosing flexibility with a dual delayed release PPI Jun Heng Lee, M.D. Samsung Medical Center, Sungkyunkwan University
More informationDepartment of Internal Medicine, Division of Gastroenterohepatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey 2
European Review for Medical and Pharmacological Sciences Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or
More informationand 2 Negma-Lerads, Toussus-le-Noble, Magny-Les-Hameaux Cedex, France INTRODUCTION
American Journal of Gastroenterology ISSN 0002-9270 C 2005 by Am. Coll. of Gastroenterology doi: 10.1111/j.1572-0241.2005.41956.x Published by Blackwell Publishing Effect on Intragastric ph of a PPI with
More informationPROTON PUMP INHIBITOR AND CLOPIDOGREL INTERACTION: Am J Gastroenterol Jan;105(1): Epub 2009 Nov 10.
PROTON PUMP INHIBITOR AND CLOPIDOGREL INTERACTION: FACT OR FICTION? 本檔僅供內部教學使用檔案內所使用之照片之版權仍屬於原期刊公開使用時, 須獲得原期刊之同意授權 Am J Gastroenterol. 2010 Jan;105(1):34-41. Epub 2009 Nov 10. Introduction Current consensus
More informationSUMMARY INTRODUCTION. Aliment Pharmacol Ther 2000; 14: 1595±1603. Accepted for publication 14 August 2000
Aliment Pharmacol Ther 2000; 14: 1595±1603. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal re ux disease (GERD)
More informationA multicentre randomised trial to compare the efficacy of omeprazole versus rabeprazole in early symptom relief in patients with reflux esophagitis
J Gastroenterol (14) 49:1536 1547 DOI 1.17/s535-13-925-8 ORIGINAL ARTICLE ALIMENTARY TRACT A multicentre randomised trial to compare the efficacy of omeprazole versus rabeprazole in early symptom relief
More informationORIGINAL ARTICLE. Abstract
ORIGINAL ARTICLE Characteristics of Refractory Gastroesophageal Reflux Disease (GERD) Symptoms Is Switching Proton Pump Inhibitors Based on the Patient s CYP2C19 Genotype an Effective Management Strategy?
More informationA. Incorrect! Histamine is a secretagogue for stomach acid, but this is not the only correct answer.
Pharmacology - Problem Drill 21: Drugs Used To Treat GI Disorders No. 1 of 10 1. Endogenous secretagogues for stomach acid include: #01 (A) Histamine (B) Gastrin (C) PGE1 (D) A and B (E) A, B and C Histamine
More informationOVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF LOSEC AND ASSOCIATED NAMES (SEE ANNEX I)
ANNEX II SCIENTIFIC CONCLUSIONS AND GROUNDS FOR AMENDMENT OF THE SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET PRESENTED BY THE EMEA 21 SCIENTIFIC CONCLUSIONS OVERALL SUMMARY OF THE
More informationNew Therapeutic Options in the Treatment of GERD and Other Acid-Peptic Disorders
...SYMPOSIUM PROCEEDINGS... New Therapeutic Options in the Treatment of GERD and Other Acid-Peptic Disorders Based on a presentation by Duane D. Webb, MD, FACG Presentation Summary Gastroesophageal reflux
More informationcompared with ranitidine
1458 Gut 1993; 34:1458-1462 CLINICAL TRIAL Department of Therapeutics, University Hospital, Nottingham C J Hawkey R G Long Rotherham District General Hospital, Rotherham K D Bardhan Ninewelis Hospital,
More informationProton Pump Inhibitors (PPIs) (Sherwood Employer Group)
Proton Pump Inhibitors (PPIs) (Sherwood Employer Group) BCBSKS will review Prior Authorization requests Prior Authorization Form: https://www.bcbsks.com/customerservice/forms/pdf/priorauth-6058ks-st-ippi.pdf
More informationAlimentary Pharmacology & Therapeutics SUMMARY
Alimentary Pharmacology & Therapeutics Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayedrelease esomeprazole capsules on nocturnal
More informationReview article: similarities and differences among delayed-release proton-pump inhibitor formulations
Aliment Pharmacol Ther 2005; 22 (Suppl. 3): 20 24. Review article: similarities and differences among delayed-release proton-pump inhibitor formulations J. R. HORN* & C. W. HOWDEN *Department of Pharmacy,
More informationDrug Class Review on Proton Pump Inhibitors
Drug Class Review on Proton Pump Inhibitors Final Report Update 4 July 2006 Original Report Date: November 2002 Update 1 Report Date: April 2003 Update 2 Report Date: April 2004 Update 3 Report Date: May
More informationEMILOK Global. (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated
EMILOK Global (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated granules. Properties: Emilok (omeprazole) belongs to the group of proton pump inhibitors, inhibits both
More informationUnmet Needs in the Management of Gastroesophageal Reflux Disease
Unmet Needs in the Management of Gastroesophageal Reflux Disease Ronnie Fass MD Professor of Medicine Case Western Reserve University Chairman, Division of Gastroenterology and Hepatology Director, Esophageal
More informationDifferent inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes
et al. DOI:1.1111/j.1365-2125.24.247.x British Journal of Clinical Pharmacology Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes Norio Yasui-Furukori, 1 Takenori
More informationDepartment of Gastroenterology, Kocaeli University School of Medicine, Kocaeli, Turkey 2
Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc ph in extensive metabolizer patients with gastroesophageal reflux disease
More informationDrug Class Review on Proton Pump Inhibitors
Drug Class Review on Proton Pump Inhibitors Evidence Tables July 2006 Original Report Date: November 2002 Update 1 Report Date: April 2003 Update 2 Report Date: April 2004 Update 3 Report Date: May 2005
More informationThe Association and Clinical Implications of Gastroesophgeal Reflux Disease and H. pylori
The Association and Clinical Implications of Gastroesophgeal Reflux Disease and H. pylori Maxwell M. Chait The relationship between GERD and H. pylori is complex and negatively associated with important
More informationHeartburn is a common symptom among adults in
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:553 563 Early Heartburn Relief With Proton Pump Inhibitors: A Systematic Review and Meta-analysis of Clinical Trials KENNETH R. MCQUAID*, and LOREN LAINE
More informationNAME OF THE MEDICINAL PRODUCT
PARIET Janssen NAME OF THE MEDICINAL PRODUCT PARIET (rabeprazole sodium) QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains: 9.42 mg rabeprazole as 10 mg rabeprazole sodium or 18.85 mg rabeprazole
More informationA model of healing of Los Angeles grades C and D reflux oesophagitis: is there an optimal time of acid suppression for maximal healing?
Alimentary Pharmacology and Therapeutics A model of healing of Los Angeles grades C and D reflux oesophagitis: is there an optimal time of acid suppression for maximal healing? P. O. Katz*, D. A. Johnson
More informationProton Pump Inhibitors. Description. Section: Prescription Drugs Effective Date: July 1, 2014
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.09.01 Subject: Proton Pump Inhibitors Page: 1 of 7 Last Review Date: June 12, 2014 Proton Pump Inhibitors
More informationDexlansoprazole MR in the Management of Gastroesophageal Reflux Disease
Clinical Medicine: Therapeutics R e v i e w Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Dexlansoprazole MR in the Management of Gastroesophageal Reflux
More informationPublic Assessment Report. Scientific discussion. Rabeprazolnatrium Torrent Pharma. 10 mg and 20 mg gastro-resistant tablets. Rabeprazole sodium
Public Assessment Report Scientific discussion Rabeprazolnatrium Torrent Pharma 10 mg and 20 mg gastro-resistant tablets Rabeprazole sodium DK/H/1819/001-002/DC This module reflects the scientific discussion
More informationOSPAP Programme. Gastrointestinal Drugs. Dr. Adrian Moore Dale
PAP Programme Dr. Adrian Moore Dale 1.03 Adrian.Moore@sunderland.ac.uk 0191 5152554 lide 1 of 26 PAP MPM14 Acid-Related Pathophysiology The stomach secretes: ydrochloric acid (Cl) aids digestion and also
More informationCAS (rabeprazole) CAS (rabeprazole sodium)
Parbezol Tablets PRODUCT INFORMATION NAME OF THE MEDICINE Rabeprazole sodium CAS-117976-89-3 (rabeprazole) CAS-117976-90-6 (rabeprazole sodium) The chemical name for rabeprazole sodium is (±) 2-[{4-(3-methoxypropoxy)-3-
More informationReview In uence of CYP2C19 Pharmacogenetic Polymorphism on Proton Pump Inhibitor-based Therapies
Drug Metab. Pharmacokinet. 20 (3): 153 167 (2005). Review In uence of CYP2C19 Pharmacogenetic Polymorphism on Proton Pump Inhibitor-based Therapies Takahisa FURUTA 1,NaohitoSHIRAI 2, Mitsushige SUGIMOTO
More informationGastro-oesophageal reflux disease and peptic ulcer disease. By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D
Gastro-oesophageal reflux disease and peptic ulcer disease By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D Gastro-oesophageal reflux disease and peptic ulcer disease Learning objectives:
More informationPACKAGE INSERT. 10mg: Each enteric-coated delayed release tablet contains 10 mg of rabeprazole sodium, equivalent
PACKAGE INSERT SCHEDULING STATUS Schedule 4 PROPRIETARY NAME (and dosage form) PARIET 10 mg tablets PARIET 20 mg tablets COMPOSITION 10mg: Each enteric-coated delayed release tablet contains 10 mg of rabeprazole
More informationThe usual dose is 40 mg daily with amoxycillin 1.5 g (750 mg b.d.) for 2 weeks. Up to 2 g/day of amoxycillin has been used in clinical trials.
Name Gasec - 2 Gastrocaps Composition Gasec-20 Gastrocaps Each Gastrocaps contains: Omeprazole 20 mg (in the form of enteric-coated pellets) Properties, effects Proton Pump Inhibitor Omeprazole belongs
More informationWe have recently shown that proton pump inhibitors
GASTROENTEROLOGY 1998;115:1335 1339 Ranitidine Controls Nocturnal Gastric Acid Breakthrough on Omeprazole: A Controlled Study in Normal Subjects PAOLO L. PEGHINI, PHILIP O. KATZ, and DONALD O. CASTELL
More informationFour-Day Bravo ph Capsule Monitoring With and Without Proton Pump Inhibitor Therapy
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:1083 1088 Four-Day Bravo ph Capsule Monitoring With and Without Proton Pump Inhibitor Therapy IKUO HIRANO, QING ZHANG, JOHN E. PANDOLFINO, and PETER J. KAHRILAS
More informationProton Pump Inhibitor De-prescribing Guidance
Amendment History Proton Pump Inhibitor De-prescribing Guidance VERSION DATE AMENDMENT HISTORY 1.0 2013 Previous version 2.0 September 2015 Comments Amendment to Flow chart and addition of Rationale page
More informationAlimentary Pharmacology and Therapeutics SUMMARY
Alimentary Pharmacology and Therapeutics The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label
More informationGERD: 2014 Dilemmas and Solutions. Ronnie Fass MD, FACP Professor of Medicine Case Western Reserve University
GERD: 2014 Dilemmas and Solutions Ronnie Fass MD, FACP Professor of Medicine Case Western Reserve University How to Maximize Your PPI Treatment? Improve compliance and adherance Fass R. Am J Gastroenterol.
More informationZABEP 20 PRODUCT INFORMATION. Name of the medicine. Description. Pharmacology
ZABEP 20 PRODUCT INFORMATION Name of the medicine Rabeprazole sodium. The chemical name is (±) 2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}- methylsulphinyl]-1h-benzimidazole sodium.. Rabeprazole has
More informationCorrelation of CYP2C19 Genetic Polymorphisms With Helicobacter pylori Eradication in Patients With Cirrhosis and Peptic Ulcer
ORIGINAL ARTICLE Correlation of CYP2C19 Genetic Polymorphisms With Helicobacter pylori Eradication in Patients With Cirrhosis and Peptic Ulcer Chii-Shyan Lay 1 *, Jiun-Rong Lin 2 1 Division of Hepatology
More informationCOMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION
Phil J Gastroenterol 2006; 2: 25-29 COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION Marianne P Collado, Ma Fatima P Calida, Peter P Sy,
More informationDrug Class Monograph
Drug Class Monograph Class: Proton Pump Inhibitors Drugs: Aciphex Sprinkle (rabeprazole), Dexilant (dexlansoprazole), Lansoprazole, Nexium (esomeprazole capsule, esomeprazole granules), Omeprazole, Pantoprazole,
More informationKafia Belhocine 1,2, Fabienne Vavasseur 1,2, Christelle Volteau 3, Laurent Flet 4, Yann Touchefeu 1,2 and Stanislas Bruley des Varannes 1,2,5*
Belhocine et al. BMC Gastroenterology 2014, 14:128 RESEARCH ARTICLE Open Access Controlling on-demand gastric acidity in obese subjects: a randomized, controlled trial comparing a single dose of 20 mg
More informationIntragastric ph With Oral vs Intravenous Bolus Plus Infusion Proton- Pump Inhibitor Therapy in Patients With Bleeding Ulcers
Intragastric ph With Oral vs Intravenous Bolus Plus Infusion Proton- Pump Inhibitor Therapy in Patients With Bleeding Ulcers LOREN LAINE, ABBID SHAH, and SHAHROOZ BEMANIAN Division of Gastrointestinal
More informationCYP2C19 VRCZ (TDM) VRCZ mg/ml mg/ml 8.61 mg/ml AST ALT mg/ml PM VRCZ CYP2C19 TDM (VRCZ)
June 2010 THE JAPANESE JOURNAL OF ANTIBIOTICS 63 13 255 ( 49 ) CYP2C19 1,2) 1) 1,2) 1,2) 2) 1) 1) 2) 2010 1 4 (voriconazole; VRCZ) CYP2C19 CYP3A4 CYP2C9 20% CYP2C19 (PM) PM VRCZ (TDM) VRCZ 15 VRCZ CYP2C19
More informationDrug Class Review Proton Pump Inhibitors
Drug Class Review Proton Pump Inhibitors Evidence Tables April 2009 Update 4: May 2006 Update 3: May 2005 Update 2: April 2004 Update 1: April 2003 Original Report: November 2002 The literature on this
More informationJNM Journal of Neurogastroenterology and Motility
JNM Journal of Neurogastroenterology and Motility J Neurogastroenterol Motil, Vol. 19 No. 1 January, 2013 pissn: 2093-0879 eissn: 2093-0887 http://dx.doi.org/10.5056/jnm.2013.19.1.25 Review Pharmacokinetics
More informationGastric ulcer: The recommended dosage is Pepzol 20 mg once daily. Symptom resolution is rapid and in most
Name Pepzol (Omeprazole) 20 mg, 40 mg Modified release (MR) Capsules Composition Each capsule Contains: Omeprazole 20 mg or 40 mg For excipients see "list of excipients" Pharmaceutical form Pepzol capsules
More informationAll pharmacodynamic effects observed can be explained by the effect of omeprazole on acid secretion.
OMEPRAZOLE Losec 10mg and 20mg Capsules Acid Pump Inhibitors FORMULATION Each capsule contains Omeprazole 10 mg or 20 mg. PHARMACEUTICAL FORM Omeprazole (LOSEC) capsule 10 mg: hard gelatin capsule with
More informationStudy population The study population comprised hypothetical patients with gastric and duodenal ulcer.
Evaluation of the cost-effectiveness of Helicobacter pylori eradication triple therapy vs. conventional therapy for ulcers in Japan Ikeda S, Tamamuro T, Hamashima C, Asaka M Record Status This is a critical
More informationMeasuring and Evaluating Indicators of Appropriate Prescribing in Older. Populations
HRB PhD Scholar Division of Population Health Sciences RCSI Measuring and Evaluating Indicators of Appropriate Prescribing in Older Cost-Effective Proton Pump Populations Potential Strategies for more
More informationAcid-suppressive drugs that
Pharmacology of acid suppression in the hospital setting: Focus on proton pump inhibition Joseph R. Pisegna, MD The more potent and longer-lasting inhibition of gastric acid secretion provided by proton
More informationPRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW
PRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW DATE OF AUTHORISATION: AUTHORISING GP: PRESCRIBING SUPPORT TECHNICIAN: SUMMARY Dyspepsia refers to a broad range of symptoms related
More informationProton Pump Inhibitors Drug Class Prior Authorization Protocol
Proton Pump Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review
More informationCytochrome P450 interactions
Cytochrome P450 interactions Learning objectives After completing this activity, pharmacists should be able to: Explain the mechanism of action of clopidogrel-ppi interaction Assess the risks and benefits
More informationH o w d o e a c t. y o u r a c i
H o w d o e a c t p a n t o p r a b r e a k d y o u r a c i Pantoprazole Sodium is the sodium salt form of a substituted benzimidazole with proton pump inhibitor activity. Pantoprazole is a lipophilic,
More informationHelicobacter pylori: Diagnosis, treatment and risks of untreated infection
Helicobacter pylori: Diagnosis, treatment and risks of untreated infection Klaus Mönkemüller Department of Gastroenterology, Hepatology und Infectius Diseases Otto-von-Guericke University, Magdeburg bb
More informationAPO- RABEPRAZOLE ENTERIC COATED TABLETS. 2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}-methylsulphinyl]-1H-benzimidazole
APO- RABEPRAZOLE ENTERIC COATED TABLETS NAME OF THE MEDICINE Rabeprazole sodium Chemical Name: (±) sodium. 2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}-methylsulphinyl]-1H-benzimidazole Structural Formula:
More informationEsomeprazole Pharmacokinetics in Patients with Cirrhosis and Healthy Controls ABSTRACT
Original Article 21 Esomeprazole Pharmacokinetics in Patients with Cirrhosis and Healthy Controls Kanlayanee Archasantisuk, M.Sc.* Sombat Treeprasertsuk, M.D., M.Sc.** Mayyuree Tantisira, Ph.D.** Arun
More informationHelicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35.
An Update on Helicobacter pylori and Its Treatment Trenika Mitchell, PharmD, BCPS Clinical Assistant Professor University of Kentucky College of Pharmacy October 18, 2008 Objectives Review the epidemiology
More informationHydroxylation of R(+)- and S( )-Omeprazole after Racemic Dosing are Different among the CYP2C19 Genotypes
Pharm Res (212) 29:231 2316 DOI 1.17/s1195-12-757-x RESEARCH PAPER Hydroxylation of R(+)- and S( )-Omeprazole after Racemic Dosing are Different among the CYP2C19 Genotypes Hideo Shiohira & Norio Yasui-Furukori
More informationTegoprazan (K-CAB) SKKUSOM 이준행
Tegoprazan (K-CAB) SKKUSOM 이준행 P-CAB (Tegoprazan, K-CAB TM ) 국내제30호신약 (code명: RQ-4, CJ-12420) Potassium Competitive Acid Blocker 위산과위산분비억제제 성균관대학교의과대학삼성서울병원소화기내과이준행 위산분비억제제개발의역사 H 2 RA Cimetidine, Ranitidine,
More informationGASTROESOPHAGEAL reflux
ORIGINAL INVESTIGATION Lansoprazole Compared With Ranitidine for the Treatment of Nonerosive Gastroesophageal Reflux Disease Joel E. Richter, MD; Donald R. Campbell, MD; Peter J. Kahrilas, MD; Bidan Huang,
More informationORIGINAL ARTICLE 3. Introduction. Methods. Orhan Sezgin 1, İ. Ömer Barlas 2, Enver Üçbilek 1, Emre Yengel 3, Engin Altintaş 1.
ORIGINAL ARTICLE 3 Modified sequential Helicobacter Pylori eradication therapy using high dose omeprazole and amoxicillin in the initial phase in the extensive metaboliser turkish patients for CYP2C9 polymorphism
More informationPharmacoeconomic analysis of proton pump inhibitor therapy and interventions to control Helicobacter pylori infection Klok, Rogier Martijn
University of Groningen Pharmacoeconomic analysis of proton pump inhibitor therapy and interventions to control Helicobacter pylori infection Klok, Rogier Martijn IMPORTANT NOTE: You are advised to consult
More informationMaastricht Ⅴ /Florence
2016 21 10 577 Maastricht Ⅴ /Florence 200001 2015 10 8 9 Maastricht V 1 / 2 3 4 / 5 Maastricht Ⅴ Interpretation of Management of Helicobacter pylori Infection the Maastricht Ⅴ / Florence Consensus Report
More informationIntroduction ORIGINAL ARTICLE. Vijayalakshmi S. Pratha 1, Thomas McGraw 2 & William Tobin 3. Abstract
ORIGINAL ARTICLE A randomized, crossover pharmacodynamic study of immediate-release omeprazole/sodium bicarbonate and delayed-release lansoprazole in healthy adult volunteers Vijayalakshmi S. Pratha 1,
More informationProton Pump Inhibitors. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.01 Subject: Proton Pump Inhibitors Page: 1 of 6 Last Review Date: June 24, 2015 Proton Pump Inhibitors
More informationNOXICID CAPS Esomeprazole (as magnesium) PRODUCT INFORMATION
Noxicid Caps Product Information 1 NOXICID CAPS Esomeprazole (as magnesium) PRODUCT INFORMATION NAME OF THE MEDICINE Active ingredient : esomeprazole magnesium Chemical name : di-(s)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1hbenzimidazole
More information